Danone account plan
global food leader health
At a glance
Danone is a French food group in dairy, plant-based, specialized nutrition and waters, with €27,283m of 2025 sales and 88,670 employees.
Danone's mission is to bring health through food to as many people as possible, through three categories: Essential Dairy & Plant-Based, Specialized Nutrition (infant formula and medical nutrition) and Waters. Its brands include Activia, Actimel, Oikos, Alpro, Silk, Aptamil, Nutricia, evian and AQUA, sold through retail chains, traditional outlets, e-commerce, away-from-home and specialised channels such as hospitals and pharmacies. In 2025 sales were €27,283m (+4.5% like-for-like), recurring operating income €3,665m (13.4% margin) and net income group share €1,825m. It had 88,670 employees at December 31, 2025 and 151 production sites. Gilles Schnepp chairs the Board and Antoine de Saint-Affrique is CEO.
Business units
Essential Dairy & Plant-Based (EDP)
48% of 2025 sales (€13,158m)Yogurts, coffee creations, desserts and plant-based drinks and alternatives under Activia, Actimel, Danone, Oikos, YoPro, Alpro and Silk. 2025 growth was +3.5% like-for-like at an 8.5% margin; high protein, Skyr and Kefir grow double-digit while North America is being turned around. H1 2026 sales were €6,681m with the margin down to 7.1% as inflation ran ahead of pricing.
Specialized Nutrition
34% of 2025 sales (€9,277m)Infant formula, complementary feeding and paediatric and adult medical nutrition (Aptamil, Nutricia, Neocate, Fortimel, Nutrison, Kate Farms), sold partly through hospitals and pharmacies. It grew +7.4% like-for-like in 2025 at a 21.7% margin, the highest category; H1 2026 sales were €4,730m. Led by Jean-Marc Magnaudet, President Specialized Nutrition.
Waters
18% of 2025 sales (€4,848m)Plain, flavoured and functional waters under evian, Volvic, AQUA, Mizone and Bonafont. 2025 growth was +1.9% like-for-like at a 10.9% margin; H1 2026 sales were €2,525m at a 13.3% margin, with Mizone soft in China.
EMEA zone
€6,133m H1 2026 salesEurope, Turkey, the Middle East, Africa and CIS, the largest zone since the January 2026 reorganisation. H1 2026 growth was +2.1% like-for-like with a 10.4% margin despite the infant formula recall. President: Pablo Perversi.
Americas zone
€4,688m H1 2026 salesNorth and Latin America, including the US medical nutrition platform built with Kate Farms. H1 2026 growth was +3.9% like-for-like at a 9.6% margin; the US yogurt, creamers and plant-based turnaround is under way. President: Henri Bruxelles.
APAC zone
€3,116m H1 2026 salesChina, Japan, Australia, New Zealand, Indonesia, Thailand, Vietnam and India, two-thirds Specialized Nutrition. H1 2026 growth was +5.6% like-for-like at a 24.7% margin. President: Bruno Chevot.
Strategic priorities
- Renew Danone Chapter 2
- Pivot categories (from yogurt to gut health and protein, from plant-based to plant-powered, from waters to healthy hydration), broaden business models such as homecare and away-from-home, and expand in the US, India and South-East Asia.
- Mid-term financial model
- For 2025-2028: 3-5% like-for-like sales growth, recurring operating income growing faster than sales, structurally double-digit ROIC and progress towards €3bn of sustainable free cash flow. 2026 guidance is in that range.
- Fix North America
- Add yogurt capacity line by line across 13 factories, relaunch Activia in H2 2026, enter kefir in the US and revive the Dannon brand with a new approach to Greek at the start of 2027, while moving Silk to the Alpro model.
- Scale medical nutrition
- Kate Farms with Nutricia forms a $500 million US medical nutrition platform; in China Danone targets deeper hospital penetration beyond tier 1.
- Strategic channels and AI
- Channels outside mass retail exceed 50% of sales and grow 2-3 times faster; AI is rolled out from Microsoft Copilot for everyone to supply chain, R&D and retailer engagement.
Latest results
In H1 2026 (six months ended June 30, 2026) sales were €13,936m, up 3.5% like-for-like and 1.4% reported, with Q2 like-for-like growth of 4.2%. Recurring operating income rose 2.3% to €1,854m and the margin to 13.3% (+12 bps), as overhead productivity offset the infant formula recall and the first inflation effects of the Middle East conflict. Net income group share rose 13.0% to €1,175m. Free cash flow fell to €852m from €1,172m as Danone built safety stocks, and net debt rose to €8,975m. 2026 guidance of 3% to 5% like-for-like growth with recurring operating income growing faster than sales was confirmed.
Investments and deals
- Kate Farms
- 96% stake acquired July 1, 2025 for €839m ($983m), a US plant-based medical and everyday nutrition brand entering like-for-like from Q3 2026.
- Huel
- Definitive agreement on March 23, 2026 to acquire the complete-nutrition brand with strong direct-to-consumer sales in the UK, Europe and the US; closing expected in H2 2026.
- MADE Group and the Australian dairy JV
- Agreement on June 22, 2026 to buy Melbourne-based MADE Group (more than €300m of sales) and the remaining 49% of Danone Saputo Dairy Australia, which together would add more than EUR400 million of sales in APAC.
- Argentina joint venture and disposals
- A March 24, 2026 agreement with Arcor combines Danone Argentina with Mastellone Hermanos in a jointly governed venture; Proviva and Lunnarp in Sweden were sold on March 2, 2026.
- Capacity capex
- Capex was €1,055m in 2025 and €414m in H1 2026, for high protein and medical nutrition capacity, and may rise to 4.5% of sales.
Challenges and risks
- Infant formula recall
- The January 2026 recall in Europe and the Middle East cost €42m of non-recurring costs in H1 2026 and has led to claims in several jurisdictions; Europe remains a mixed bag.
- Middle East conflict and cost inflation
- The conflict disrupts logistics in the region and raises energy, transport, packaging and some raw material costs; the EDP margin fell 68 bps in H1 2026 before price increases.
- US EDP competitiveness
- The CEO has stated dissatisfaction with parts of the North American EDP portfolio: coffee creamers, plant-based (Silk) and non-protein yogurt starved of capacity.
- China dependence
- China is about 12% of sales and the largest profit contributor, and infant formula sold there is mostly made abroad; Mizone was a drag in Q2 2026.
What leadership says
“the food industry is at a tipping point and health through food has never been more relevant”
“It is clear that in the US, our performance in 2025 didn't meet our expectations. We are not where we should be, and we know we need to step up our game.”
“Protein is here to stay. Penetration of GLP-1 is still nowhere”
“volume, volume, volume and mix will remain our priority number one”
Where a supplier can help
- Supply chain resilience
- Safety stocks built against Middle East disruption and higher packaging and energy costs make supply planning, sourcing and logistics optimisation suppliers relevant to that challenge.
- US capacity ramp-up
- The North America fix depends on adding yogurt capacity line by line across 13 factories: equipment, automation and manufacturing-execution vendors fit this priority.
- Direct-to-consumer and community marketing
- Huel brings direct-to-consumer and community capabilities Danone says it lacks; e-commerce, content and community-management tools can support the integration and the push into strategic channels.
- Healthcare channel reach
- Scaling medical nutrition through hospitals, pharmacies and healthcare professionals in the US and China calls for medical sales enablement, health economics and HCP engagement partners.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Danone?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Universal Registration Document 2025 (Annual Financial Report)
- Danone is a health-focused food group with three categories: Essential Dairy & Plant-Based (EDP, 48% of 2025 sales, €13,158m), Specialized Nutrition (infant formula and medical nutrition, 34%, €9,277m) and Waters (18%, €4,848m). It is no. 1 worldwide in fresh dairy and in plant-based foods and beverages, no. 2 in packaged waters and early life nutrition, no. 4 in adult medical nutrition. 88,670 employees and 151 production sites at end 2025.
- FY2025: sales €27,283m, +4.5% like-for-like (volume/mix +2.7%, price +1.8%) but -0.3% reported after a -5.0% currency effect; recurring operating income €3,665m, margin 13.4% (+44 bps); recurring EPS €3.80 (+4.6%); free cash flow €2,799m; ROIC 10.7% (+62 bps); dividend €2.25 (+4.7%). Reported net income fell 9.7% to €1,825m because of €725m of non-recurring costs (transformation projects in Europe and Indonesia, impairments).
- Growth by zone (LFL): Europe +2.3% (36% of sales), North America +2.0% (23%, "softer growth"), China, North Asia & Oceania +11.7% (14%, entirely volume/mix), Latin America +6.0%, Asia-Middle East-Africa +5.6%. By category: EDP +3.5% (margin 8.5%), Specialized Nutrition +7.4% (margin 21.7%, +112 bps), Waters +1.9% (margin 10.9%).
- The United States is the largest country (20% of sales), China second (12%, and the largest profit contributor); the top-5 markets are 51% of sales. The top ten customers are about 20% of sales, the top five about 14%. Channels outside mass retail (pharmacies, hospitals, homecare, away-from-home, e-commerce) are now over 50% of sales and grew 2-3x faster than mass retail in 2025.
- Strategy: "Renew Danone" Chapter 2 (since June 2024) pivots categories towards protein and gut health, broadens business models (away-from-home, medical nutrition, homecare), expands in the US, India and South-East Asia, and moves "to the front foot" on M&A. Mid-term guidance 2025-2028: 3-5% LFL sales growth, recurring operating income growing faster than sales, structurally double-digit ROIC, long-term ambition of €3bn free cash flow.
- 2025 M&A: 96% of Kate Farms (US plant-based medical nutrition, no. 1 doctor-recommended) for €839m ($983m) on July 1, 2025, creating a US medical nutrition platform; The Akkermansia Company (biotics, Belgium); disposal of the Iranian dairy business (€77m loss); sale of Proviva/Lunnarp (Sweden) signed. Capex rose to €1,055m, mostly capacity for high protein and medical nutrition.
- Organisation: from January 1, 2026 Danone runs three zones (EMEA, Americas, APAC) instead of five; Shane Grant (Deputy CEO, CEO Americas) left in June 2025. Early 2026 events: targeted recall of infant formula batches (January 23, 2026) and consolidation of the Australian dairy JV with Saputo at 51% (February 12, 2026).
- Main risks rated "strong": over-reliance on principal markets (notably China, where infant formula sold is mostly made abroad), packaging/plastics regulation, fast changes in consumer preferences, raw material and energy price volatility (materials are ~75% of COGS, about €10bn a year), climate change. Medium: retail shift (discounters, private label), currency, legal/regulatory, cybersecurity, food safety, talent, business transformation.
- 2026 guidance: like-for-like sales growth of 3% to 5% with recurring operating income growing faster than sales. CEO Antoine de Saint-Affrique: "there is more to do and some areas still require further progress."
- 2026 Interim Financial Report (six months ended June 30, 2026)
- H1 2026 sales €13,936m, +3.5% like-for-like (volume/mix +1.7%, price +1.8%), +1.4% reported with a +0.7% scope effect (Kate Farms, Australian dairy JV) and -3.3% from currencies.
- Recurring operating income €1,854m, margin 13.3% (+12 bps): strong productivity gains including +84 bps in overheads offset a -54 bps fall in margin from operations (infant formula recall in EMEA, first effects of inflation) and -25 bps of reinvestment in A&P, product superiority and capabilities.
- New three-zone reporting: EMEA €6,133m (+2.1% LFL, margin 10.4% flat), Americas €4,688m (+3.9%, margin 9.6%, +31 bps), APAC €3,116m (+5.6%, margin 24.7%). By category: EDP €6,681m (+3.6%, margin 7.1%, -68 bps), Specialized Nutrition €4,730m (+3.2%, margin 22.1%), Waters €2,525m (+3.6%, margin 13.3%, +196 bps).
- Recurring EPS €1.92 (+0.9%); reported net income group share €1,175m (+13.0%), helped by a €122m remeasurement gain on the Australian JV; non-recurring operating expense -€161m (transformation projects €82m, recall costs €42m).
- Free cash flow €852m (vs €1,172m): capex up to €414m and a -€567m working capital outflow from security stocks built up because of the Middle East situation. Net debt €8,975m (+€544m since December); €1.6bn triple-tranche bond issued in March; dividend of €2.25 paid in May (€1,440m).
- Deals signed and pending close in H2 2026: acquisition of Huel (complete nutrition, UK/Europe/US, direct-to-consumer), acquisition of MADE Group (Australia, >€300m sales, high-protein RTD, gut-health yogurts, coconut products) and of the remaining 49% of the Saputo dairy JV, and a dairy joint venture with Arcor in Argentina that deconsolidates Danone Argentina (assets held for sale €240m).
- Risks: no new risk factors, but the Middle East conflict that began in February 2026 is disrupting logistics and inflating energy, transport, packaging and some agricultural costs; the January 2026 infant formula recall has triggered claims in several jurisdictions, with no provision booked.
- 2026 guidance confirmed: like-for-like sales growth of 3% to 5% with recurring operating income growing faster than sales.
- H1 2026 results conference call transcript (CEO Antoine de Saint-Affrique, CFO Juergen Esser)
- Q2 2026 like-for-like sales +4.2% (volume/mix +1.9%, positive in every region and category), reported +4.4% to €7.2bn with scope +0.8% (Kate Farms, Australian JV) and currency -1%; H1 LFL +3.5%, recurring operating margin 13.3% (+12 bps), recurring EPS €1.92 (+0.9%), free cash flow €0.9bn.
- Q2 by category: EDP +3.8%, Specialized Nutrition +4.5% (medical nutrition strong everywhere; infant formula in Europe and the Middle East recovering since mid-Q2), Waters +4.7% (Volvic, Aqua Indonesia). By zone: EMEA +3.6%, Americas +4.3% (North America +2.6%), APAC +5.2% (Mizone down in a soft Chinese waters season).
- Growth engines: high protein double-digit in all regions, Skyr and Kefir double-digit in Europe, Alpro high single-digit, medical nutrition brands Nutrison, Fortimel and Neocate high single to double-digit; away-from-home, hospitals, pharmacies and home care grow 2-3x faster than mass retail.
- North America EDP: "still only at the beginning of the journey"; yogurt lines come on stream line by line through 2026, Activia relaunch in H2, Oikos new formats, International Delight renovation in 2027, Silk repositioned as "plant-powered" with protein yogurt and shakes; creamers have stabilised; "everything that is protein is absolutely absolutely flying".
- M&A under three filters (strategic fit, financial discipline with double-digit ROIC, execution capability): Huel (premium complete nutrition, direct-to-consumer and community skills, 300-400 digital assets a month), MADE Group plus the rest of the Australian JV (doubles APAC EDP, adds more than €400m of sales, accretive to margin and EPS from year one), Argentina JV with Arcor (deconsolidates, EPS-accretive over time); all closing in H2 2026.
- Margin: EDP margin down about 70 bps in H1 because inflation (energy, packaging) arrived before pricing; selective price increases roll out in Q3; hedging protects Specialized Nutrition and Waters more than dairy. Inventory rose about 250 million as security stocks against Middle East supply disruption, to unwind in the coming quarters; capex up €40-50m for medical nutrition and high protein.
- China: infant formula market "normalizing" after the Year of the Dragon, shares gaining via Essensis premiumisation; super-premium Nuturis launching in mainland China after Hong Kong; medical nutrition (tube feeding leadership, pediatrics, oral nutrition) "only at the start of the journey"; volume-based procurement is "business as usual".
- 2026 guidance confirmed: 3-5% LFL growth, recurring operating income faster than sales; no margin guidance ("our guidance is our guidance is our guidance").
- FY 2025 results conference call transcript (CEO Antoine de Saint-Affrique, CFO Juergen Esser)
- 2025, the first year of Renew Danone Chapter 2: like-for-like sales +4.5% with volume/mix +2.7%, recurring operating margin 13.4% (+44 bps, margin from operations +77 bps), recurring EPS €3.80 (+4.6%), free cash flow €2.8bn, ROIC 10.7% (+62 bps), dividend €2.25 (+5%); Q4 LFL +4.7%. Reported sales flat at €27.3bn after -4.4% currency.
- The call opened on the January 2026 infant formula recall (batches in Europe and the Middle East, under new authorities' requirements on cereulide): "food safety and quality are ... our top priority"; no significant stock returns, but shelf disruption at European retailers expected to cost 0.5-1% of group sales in Q1 2026, normalising in March; no products sold through official channels in China affected.
- Growth engines: Oikos Pro exceeded €1bn of revenue in the US; the Danone brand passed €1bn with high single-digit growth; Alpro is a €1bn platform; Aptamil grew double-digit and doubled in Vietnam; Fortimel and Nutrison form a fast-growing billion-euro medical nutrition platform; specialised channels (pharmacies, hospitals, home care) grew double-digit.
- Zones: Europe +2.3% with nine consecutive quarters of positive volume/mix, margin 12.0%; CNAO +11.7%, entirely volume/mix, margin 29.2%; North America +2.0% and only +0.7% in Q4, margin 11.0% (-39 bps) - "we are not where we should be"; Latin America +6.0%, margin up nearly 3 points to 6.4%; AMEA +5.6%.
- North America fixes: new Americas President Henri Bruxelles and deep leadership change (the head of the Alpro turnaround now runs US categories and creamers), Two Good clean-label creamers, Danimals relaunch, yogurt capacity added line by line; creamers to return to growth from Q2 2026 as comps ease. CEO: "I expect the end of not invented here and rapid movements in the US."
- Kate Farms plus Nutricia is now a $500m US medical nutrition platform growing strong double-digit, entering like-for-like from Q3 2026; the Australian dairy JV with Saputo (YoPRO, Activia, Ultimate, over €100m of revenue) is consolidated at 51%. Japan is a €400m EDP business growing strong double-digit on Oikos and Activia.
- Capex to rise from just under 4% to up to 4.5% of sales for high-protein and medical nutrition capacity; working capital at -10% of sales is "best-in-class". EDP margin target is "double-digit territory" but gross margin gains are being reinvested; whey and lactose inflation weighed on H2 gross margin.
- 2026 guidance: +3% to 5% like-for-like with recurring operating income growing faster than sales - "boringly consistent" since 2022.
- Fireside chat at the dbAccess Global Consumer Conference 2026 (Deutsche Bank) with CEO Antoine de Saint-Affrique and CFO Juergen Esser
- Backdrop unchanged despite the Middle East conflict and the Q1 infant formula recall: "the foods market is at a tipping point. People realize that they are what they eat"; ageing, mobility needs and cancer incidence drive demand. Q1 was "exceptional" but changes nothing in guidance or business model; the organisation is focused on volume/mix growth.
- Productivity is a "competitive edge" that funds reinvestment; pricing in response to inflation will be "as limited as possible and as selective as possible", with no large-scale restructuring ("silent restructuring when we need to"), using the Ukraine-war playbook.
- Mix comes from three sources: category mix (medical nutrition is accretive to growth and gross margin), innovation mix (high protein, Activia variants) and channel mix - hypermarkets went from about 55% of sales five years ago to 45% today, pharmacies carry better mix.
- US yogurt: per-capita consumption is about a third of Europe's; protein is "a trend that is here to stay", pushed by health, US government support for milk protein and GLP-1 access; next trends are gut health, kefir, pre- and probiotics and fibre. The Danone brand, "a bit of a sleeping beauty in the US" since 1942, is a billion-euro platform growing double-digit in Europe and Latin America and "has not been leveraged at all so far in the US". Improvement in North America will be "progressive ... quarter by quarter".
- US plant-based: Silk never got the Alpro repositioning from ingredient-led and anti-milk to benefit-led; new teams since January are deploying the Alpro playbook (the moderator referred to the announced closure of the New Jersey facility), and the CEO expects "progress in the next 12 months". Danone sold its stake in Lifeway but may return to kefir in the US.
- Adult medical nutrition grows high single to double-digit every quarter; Danone is no. 1 in China and Europe, investing in sales forces to reach tier 2-3 hospitals and pharmacies; with Kate Farms Danone has been "buying our route to market in the US". No interest in buying a large US infant formula business because of its liabilities: "ROIC, ROIC, ROIC".
- China infant formula: a market still worth about €20bn ten years on while births fell from 14 million to below 8 million; 1,000 players have become about 500, top three hold about 50% versus 70%+ elsewhere, so consolidation and science-led premiumisation (Essensis, Nuturis) continue; the Year of the Dragon was "a blip".
- ROIC went from 7.5% four years ago to over 10%; Kate Farms and Huel are expected to be EPS-accretive after 12 months. No margin-percentage guidance by design: managing to a KPI "you start cutting advertising, cutting in R&I".
- AI: everyone on Microsoft Copilot in a sandbox; AI in R&D (1,200 ferments), marketing, consumer care (a stool tracker), forecasting; Opole (Poland) is one of the most digital nutrition factories; AI image recognition for store checks; the group is planning reskilling for a decade in which "80% of the jobs would have changed". "We are not at peak protein."
- Fireside chat at an investor conference in Boston (September 8, 2026) with CEO Antoine de Saint-Affrique and CFO Juergen Esser, moderated by Warren Ackerman (Barclays)
- Renew Danone Chapter 2 in the CEO's words: "Danone is only doing one thing. We do health through food to as many people as possible", anchored in science; three moves - pivot how categories are seen (protein: Oikos Pro is $1bn-plus; gut health: Activia back to growth; plant-based to plant-powered: Alpro), broaden reach (large mass retail fell from about 60% of sales to closer to 40%, "the key driver of our resilience") and keep expanding via health-centred acquisitions. "We live in a world of constructive dissatisfaction."
- H2 2026 variables: Kate Farms enters like-for-like, the early-life nutrition recall fades, North America improves progressively; Mizone was a drag in Q2 and probably Q3 in a poor Chinese beverage season while Indonesia was strong. Esser: "very confident to deliver within our guidance in the short, medium and long term"; the CEO: the 3-5% band "gives us the flexibility to do the difficult right rather than the easy wrong".
- North America EDP is about 7% of group sales; capacity comes on "one line after the other" across 13 factories and should be a non-topic in five to six months; the plan is to play "a Danone game": protein in new formats, fibre and pre/probiotics with Activia, kefir in the US "in the coming months", and a revival of the Dannon brand with a new Greek approach at the start of 2027. Capacity takes 12-18 months to build; the CFO is "very bullish" on EDP globally (H1 +3.6%, Europe consistent, Japan and Latin America fast).
- Europe EDP: Activia revival is "a long haul journey" but back to growth on fibre and kefir; kefir will be a $100m-plus platform; Skyr combines naturalness and protein. US plant-based: Silk is being moved towards the Alpro model by a new team; "we need to see progress in a relatively short period of time."
- Infant formula recall: the Middle East bounced back in Q2 to prior distribution and shares; Europe is "a mixed bag" with a slower category and shares won in some countries and lost in others, expected to level out; in China social media drove a shift from international to China label, where Danone plays both.
- China: the infant formula market is still about €20bn with 7-8 million births versus 14 million before; premiumisation, urban penetration and consolidation (top three about 50%) still allow growth; Specialized Nutrition China should return to a mid-single-digit contribution; Danone went from no. 4-5 to co-leader in early life nutrition; Essensis is "probably halfway" to full distribution and Nuturis launches in waves; people over 60 in China will go from 250 million (2023) to 300 million (2030) and 350 million (2040), rebalancing the business towards medical nutrition.
- Early life nutrition is one-third China, one-third Europe, one-third rest of world; the latter grows high single to double-digit, is "very profitable" and 95% Aptamil, with investment in Latin America, the Middle East, India and South-East Asia. India has 23 million births a year: "If you want to be relevant in the long term, you need ... critical mass and presence there", built profitably.
- Margins: COGS inflation (packaging, energy, protein) is real and hard to size; levers are productivity, pricing "as we speak in many, many markets" and above all volume/mix; EDP margin should rise over the next years as pricing lands and North America recovers; the pivot from spoonable to drinkable and now "out of the fridge" (Huel, Alpro Meal to Go, ambient protein shakes) opens "a new, very profitable universe".
- Deals: Kate Farms gives a truly superior product and access to more than 1,500 hospitals; Huel brings a "Hueligans" community, 300-400 ads a month and influencer skills, with Danone adding science and distribution; MADE Group is "a mini-Danone" adding about 400 million in Australia, New Zealand and South-East Asia. The CEO reiterated he is "not interested" in the US part of a particular infant formula target because of legal and factory liabilities and a different business model.
Questions about Danone
What does Danone do?
Danone makes dairy and plant-based products, infant and medical nutrition, and bottled waters, with brands such as Activia, Oikos, Alpro, Aptamil, Nutricia and evian.
What is Danone's revenue?
Sales were €27,283m in 2025 and €13,936m in H1 2026, up 3.5% like-for-like.
How many employees does Danone have?
Danone had 88,670 employees at December 31, 2025.
Who leads Danone?
Antoine de Saint-Affrique is CEO, Juergen Esser is Deputy CEO and CFO, and Gilles Schnepp chairs the Board.
What is Danone's strategy?
Renew Danone Chapter 2 pivots the portfolio to health categories such as protein, gut health and medical nutrition, broadens channels and expands in the US and emerging markets, targeting 3-5% like-for-like growth.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)